<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651765</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-022</org_study_id>
    <nct_id>NCT03651765</nct_id>
  </id_info>
  <brief_title>Long Term Extension Trial of Setmelanotide</brief_title>
  <official_title>Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term extension trial to study the safety and tolerability of continued&#xD;
      setmelanotide treatment in patients who have completed a previous clinical trial on treatment&#xD;
      with setmelanotide for obesity associated with genetic defects upstream of the MC4 receptor&#xD;
      in the leptin-melanocortin pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this protocol is to continue the assessment of setmelanotide treatment in&#xD;
      patients who have successfully completed all critical study evaluations in a prior trial&#xD;
      (index protocol) of setmelanotide for the treatment of obesity associated with genetic&#xD;
      defects in the leptin-melanocortin pathway upstream of the MC4 receptor. The primary&#xD;
      objectives of this extension trial are to explore the long-term safety and tolerability of&#xD;
      setmelanotide for up to 5 years or until drug is otherwise available through authorized use.&#xD;
      Patients can enter this protocol immediately upon completion of their index protocol such&#xD;
      that dosing of setmelanotide continues without gaps in therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of setmelanotide</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency and severity of adverse events (AEs) as well as changes in physical examinations, electrocardiograms (ECGs), vital signs (including resting BP and HR), laboratory evaluations, and injection site reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>2 years</time_frame>
    <description>Maintenance or continued weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of hunger using a Hunger Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Mass</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of body composition as measured by bioelectrical impedance (BIA) or Dual-energy x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total body mass, non-bone lean mass, and bone density</measure>
    <time_frame>2 years</time_frame>
    <description>Percent change in total body mass, non-bone lean mass, and bone density measured in kg and waist circumference .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Labs</measure>
    <time_frame>2 years</time_frame>
    <description>Changes in fasting lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of quality of life measured by quality of life questionnaires (IWQOL for adults and PEDSQL for pediatrics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Health Status</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment of health status measured by the SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assays</measure>
    <time_frame>2 years</time_frame>
    <description>Assays to be collected and analyzed: LH, FSH, TSH, free T4, IGF-1, IGFBP-3, Serum procollagen type 1 N-propeptide, COOH-terminal telopeptide of type 1 collagen, N-terminal telopeptide of type 1 collagen, Bone-specific alkaline phosphatase, osteocalcin.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obesity Associated With Defects in Leptin-melanocortin Pathway</condition>
  <arm_group>
    <arm_group_label>Setmelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Setmelanotide</intervention_name>
    <description>Once daily subcutaneous injection</description>
    <arm_group_label>Setmelanotide</arm_group_label>
    <other_name>RM-493</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 6 or older that have completed participation on active drug and&#xD;
             demonstrated adequate safety and meaningful clinical benefit (efficacy) in a previous&#xD;
             setmelanotide study for obesity associated with genetic defects upstream of the MC4&#xD;
             receptor in the leptin-melanocortin pathway.&#xD;
&#xD;
             Note: The index study may have a primary endpoint relied on efficacy, safety or&#xD;
             tolerability. Patient will be eligible for extension study if the Primary Investigator&#xD;
             believes the patient exhibited a clinically meaningful benefit (i,e, efficacy) to&#xD;
             setmelanotide treatment, and would benefit from continued treatment, after discussion&#xD;
             with the Sponsor.&#xD;
&#xD;
          2. Study participant and/or parent or guardian is able to communicate well with the&#xD;
             investigator, to understand and comply with the requirements of the study, and to&#xD;
             understand and sign the written informed consent/assent. The patient must&#xD;
             assent/consent to participate in the trial.&#xD;
&#xD;
          3. Female participants of child-bearing potential must agree to use contraception as&#xD;
             outlined in the protocol. Female participants of non-childbearing potential, defined&#xD;
             as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral&#xD;
             tubal ligation), postmenopausal for at least 12 months (and confirmed with a screening&#xD;
             FSH level in the postmenopausal lab range), or have delayed pubertal development and&#xD;
             failure to have achieved menarche, do not require contraception during the study. Any&#xD;
             female participant in this latter category of having failed to reach menarche upon&#xD;
             study entry and who now suspects this status may have changed should promptly inform&#xD;
             the investigator and undergo pregnancy testing. All patients must agree to follow&#xD;
             requirements for contraception outlined in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant and/or breastfeeding women&#xD;
&#xD;
          2. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions&#xD;
             (excluding non-invasive basal or squamous cell lesion), determined as part of a&#xD;
             screening comprehensive skin evaluation performed by a qualified dermatologist. Any&#xD;
             concerning lesions identified during the screening period will be biopsied and results&#xD;
             known to be benign prior to enrollment. If the pre-treatment biopsy results are of&#xD;
             concern, the patient may need to be excluded from the study.&#xD;
&#xD;
          3. Patient is, in the opinion of the Study Investigator, not suitable to participate in&#xD;
             the study. In addition, any patient who experiences a gap in treatment of at least one&#xD;
             month between completing the Index study and Screening for this study, should have the&#xD;
             following exclusion criteria evaluated:&#xD;
&#xD;
          4. Current, clinically significant disease, if severe enough to interfere with the study&#xD;
             and/or would confound the results. Any such patients should be discussed with the&#xD;
             Sponsor prior to inclusion&#xD;
&#xD;
          5. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic&#xD;
             and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator&#xD;
             believes will interfere significantly with study compliance.&#xD;
&#xD;
          6. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.&#xD;
&#xD;
          7. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale&#xD;
             (CSSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the&#xD;
             last month. Note: Patients who are unable to complete the PHQ-9 or C-SSRS due to&#xD;
             significant neurocognitive defects may be enrolled in the study, as long as in the&#xD;
             opinion of the Primary Investigator there are no clinical signs or symptoms of&#xD;
             suicidal behavior.&#xD;
&#xD;
          8. History of significant liver disease or liver injury, or a current liver assessment&#xD;
             due to abnormal liver tests (as indicated by abnormal liver function tests, alanine&#xD;
             transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase, or serum&#xD;
             bilirubin &gt;1.5× the upper limit of normal [ULN] for any of these tests) for an&#xD;
             etiology other than nonalcoholic fatty liver disease (NAFLD). Thus, any underlying&#xD;
             etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH),&#xD;
             other causes of hepatitis, or history of hepatic cirrhosis is exclusionary, but the&#xD;
             presence of NAFLD is not be exclusionary.&#xD;
&#xD;
          9. Moderate to severe renal dysfunction as defined by a glomerular filtration rate (GFR)&#xD;
             &lt;30 mL/min.&#xD;
&#xD;
         10. History or close family history (parents or siblings) of skin cancer or melanoma (not&#xD;
             including non-invasive/infiltrative basal or squamous cell lesion), or patient history&#xD;
             of ocular-cutaneous albinism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Stewart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhura Srinivasan</last_name>
    <phone>+1 857-701-3713</phone>
    <email>msrinivasan@rhythmtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Gray</last_name>
      <phone>480-775-1115</phone>
      <phone_ext>4324</phone_ext>
      <email>Stephanie.Gray@synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Randall Severance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Boone</last_name>
      <phone>480-323-4936</phone>
      <email>Steven.Boone@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Janes Swain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Diego Wake Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Davis</last_name>
      <phone>352-294-5280</phone>
      <email>davisca@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Hatfield Clinical Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Brady</last_name>
      <phone>301-451-3783</phone>
      <email>bradys@mail.nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlin Ballenger</last_name>
      <phone>301-496-6726</phone>
      <email>kaitlin.ballenger@nih.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Jack Yanovski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Cobb</last_name>
      <email>victoria.cobb@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Rushika Conroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda House</last_name>
      <phone>716-323-0075</phone>
      <email>ahouse@upa.chob.edu</email>
    </contact>
    <investigator>
      <last_name>Indrajit Majumdar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anah Kim</last_name>
      <phone>212-342-4622</phone>
      <email>ak3578@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Layer</last_name>
      <phone>919-668-1546</phone>
      <email>marcus.layer@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Freemark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aubrey Farray</last_name>
      <phone>919-781-2514</phone>
      <email>afarray@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obesity Institute, Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Yohn</last_name>
      <phone>570-214-1004</phone>
      <email>mmyohn2@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Still, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadephia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Wade</last_name>
      <phone>267-426-8724</phone>
      <email>wadekl@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Shana McCormack</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc.- Primary Care Associates, PC</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Harrison</last_name>
      <phone>864-305-1411</phone>
      <email>Kristina.Harrison@Synexus-us.com</email>
    </contact>
    <investigator>
      <last_name>Erin Cooksey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research TN</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisela Heintz</last_name>
      <phone>423-698-4584</phone>
      <email>gheintz@clinsearch-us.com</email>
    </contact>
    <investigator>
      <last_name>Mark McKenzie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Mack</last_name>
      <phone>901-287-6869</phone>
      <email>rmack7@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Ahlee Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Maynard</last_name>
      <phone>615-875-4274</phone>
      <email>laura.e.maynard@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Citrine Elatrash</last_name>
      <phone>713-798-9316</phone>
      <email>citrine.elatrash@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Sisley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Kearns</last_name>
      <phone>206-987-1758</phone>
      <email>sue.kearns@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Christian Roth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Institute</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Johnson</last_name>
      <phone>715-389-5479</phone>
      <email>Johnson.nathan@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Robert Haws, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Lyster</last_name>
      <phone>780-248-1770</phone>
      <email>clyster@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Andrea Haqq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peel Memorial Hospital</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlee Trafford</last_name>
      <email>Karlee.Trafford@illingworthresearch.com</email>
    </contact>
    <investigator>
      <last_name>Allison Bahm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Dubern</last_name>
      <phone>33 (1) 44 73 64 46</phone>
      <email>beatrice.dubern@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Beatrice Dubern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Clement</last_name>
      <phone>01 4217 70 31</phone>
      <email>karine.clement@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Karine Clement</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13354</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlett Stielow</last_name>
      <phone>+49 30 450 616 124</phone>
      <email>arlett.stielow@charite.de</email>
    </contact>
    <investigator>
      <last_name>Peter Kuhnen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Ott</last_name>
      <phone>+49 341 97 2 68 34</phone>
      <email>Kerstin.Ott@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Antje Korner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Kleger</last_name>
      <phone>+49 731 500 57401</phone>
      <email>pauline.kleger@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Martin Wabitsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Rio</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conny Kaal-Alfenaar</last_name>
      <phone>+31 10 7036587</phone>
      <email>c.kaal@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Erika Van den Akker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Autónoma de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>65 28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Ventosino Perez</last_name>
      <phone>+34 616 531 224</phone>
      <phone_ext>7351</phone_ext>
      <email>nuria.ventosino@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Jesus Argente</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Angel Martos-Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus Pozo Roman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amalia Tamariz Martell-Moreno</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Hernandez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun Bolton</last_name>
      <phone>0044 121-371-6795</phone>
      <email>shaun.bolton@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tarekegn Hiwot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust-MRC Institute of Metabolic Science</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Henning</last_name>
      <phone>44 (0) 1223 762634</phone>
      <email>eh330@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Lynne Stanley</last_name>
      <phone>44 (0)1223 762634</phone>
      <email>ls824@medschl.cam.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Sadaf Farooqi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aime Boakye</last_name>
      <phone>44 (0) 203 31331312</phone>
      <email>aime.boakye@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tony Gladstone</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicola Bridges</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>setmelanotide</keyword>
  <keyword>RM-493</keyword>
  <keyword>obesity</keyword>
  <keyword>leptin-melanocortin</keyword>
  <keyword>melanocortin 4 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

